BANGALORE, May 14 (Reuters) – Critical Therapeutics Inc. <CRTX> said U.S. regulators approved a respiratory care product of its partner, Dey L.P, that treats chronic obstructive pulmonary disease.
Dey is an affiliate of Germany's Merck KGaA[it will become part of MYL]. Under a co-promotion agreement, Critical Therapeutics will help promote Dey's Perforomist inhalation product for the treatment of bronchoconstriction for emphysema and chronic bronchitis in the United States, the company said in a statement.
Pacific Growth Equities analyst Greg Wade feels the stock is up on the combined effect of Dey's product approval and expectation that Critical's zileuton CR, a reformulation of its primary drug, will get approval from the U.S. Food and Drug Administration at the end of this month.
Wade said Critical needs to expand its sales force to start selling Perforomist and for that its needs approval of zileuton CR, the reformulation of ZYFLO, an asthma treatment. Critical is looking to expand its sales force to at least 40 to promote Perforomist.
Dey and Critical also have a co-promotion agreement for ZYFLO.
Cowen & Co. analyst Ian Sanderson said people are expecting zileuton CR to get approval, which means Critical has two new products coming up in its third quarter. <<
News 
Market Data 
Discover 
